SystImmune Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Jie D’Elia, Ph.D., MBA, as its new Chief Executive Officer.

Experience

With a career spanning over two decades in the biopharmaceutical industry, D’Elia most recently served as Senior Vice President for business development in oncology, hematology, and cell therapy at Bristol Myers Squibb (BMS).
 
D’Elia spent over a decade at BMS where she made contributions to BMS’s pipeline evolution through multiple strategic partnerships and acquisitions in therapeutic areas ranging from oncology, cardiovascular, virology, fibrosis, and cell therapy.
 
Prior to BMS, D’Elia served as the Vice President and Global Head of Business Development at Simcere Pharmaceutical. She previously worked at AstraZeneca, Boston Consulting Group and Baxter Healthcare. Throughout her career in the biopharmaceutical industry, she has orchestrated over $40 billion in strategic partnerships and mergers and acquisitions, leveraging her strong business expertise and deep industry knowledge.
 
D’Elia received her Ph.D. from the College of Pharmacy at the University of Texas at Austin and her MBA from Columbia Business School.
 
Dr. Yi Zhu, Chairman of SystImmune, said, “Jie is an accomplished leader with a proven track record of developing business strategy, forging strategic collaborations, and cultivating high-performing teams. I look forward to working with her as we steer SystImmune towards new horizons of development and success.”
 
“SystImmune has carved a niche in the biopharmaceutical landscape with its success in developing first-in-class and best-in-class therapeutics,” said D’Elia. “Its highly differentiated platforms discovering bi-specific and multi-specific antibodies and ADCs stand out as a testament to its innovative capabilities. I am honored to join this accomplished team and am committed to advancing our pipeline of therapeutics to bring new treatment paradigms for patients in need.”